Vertex Pharmaceuticals (VRTX)
(Real Time Quote from BATS)
$484.33 USD
-1.20 (-0.25%)
Updated Jun 7, 2024 02:38 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Vertex Pharmaceuticals (VRTX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Downside to Average Price Target |
---|---|---|---|
$458.73 | $577.00 | $325.00 | -5.52% |
Price Target
Based on short-term price targets offered by 26 analysts, the average price target for Vertex Pharmaceuticals comes to $458.73. The forecasts range from a low of $325.00 to a high of $577.00. The average price target represents a decline of 5.52% from the last closing price of $485.53.
Analyst Price Targets (26)
Broker Rating
Vertex Pharmaceuticals currently has an average brokerage recommendation (ABR) of 1.83 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 29 brokerage firms. The current ABR compares to an ABR of 1.87 a month ago based on 30 recommendations.
Of the 29 recommendations deriving the current ABR, 19 are Strong Buy, representing 65.52% of all recommendations. A month ago, Strong Buy represented 63.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 19 | 19 | 19 | 19 | 17 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 8 | 8 | 9 | 9 | 9 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 2 | 2 | 2 | 2 | 2 |
ABR | 1.83 | 1.83 | 1.87 | 1.87 | 1.93 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/31/2024 | BMO Capital Markets | Evan Seigerman | Strong Buy | Strong Buy |
5/7/2024 | SVB Securities | David Risinger | Strong Buy | Strong Buy |
5/7/2024 | Truist Securities | Joon Lee | Strong Buy | Strong Buy |
5/7/2024 | Cantor Fitzgerald & Co | Olivia Brayer | Strong Buy | Strong Buy |
4/12/2024 | Canaccord Genuity | Whitney Ijem | Strong Sell | Strong Sell |
4/11/2024 | Piper Sandler | Christopher Raymond | Strong Buy | Strong Buy |
4/11/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
4/11/2024 | Evercore Partners | Liisa A Bayko | Hold | Strong Buy |
4/1/2024 | Needham & Company | Joseph R Stringer | Hold | Hold |
3/10/2024 | Guggenheim Securities | Debjit Chattopadhyay | Strong Buy | Strong Buy |
2/6/2024 | William Blair | Myles R Minter | Strong Buy | Strong Buy |
1/31/2024 | Robert W. Baird & Co. | Brian P Skorney | Hold | Strong Sell |
1/30/2024 | Maxim Group | Naz Rahman | Strong Buy | Hold |
1/3/2024 | Argus Research Corp. | Jasper Hellweg | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.83 |
ABR (Last week) | 1.83 |
# of Recs in ABR | 29 |
Average Target Price | $458.73 |
LT Growth Rate | 12.80% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 83 of 252 |
Current Quarter EPS Est: | 4.09 |